Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia: Technology appraisal guidance [TA541] – NICE

Evidence-based recommendations on inotuzumab ozogamicin (Besponsa) for relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adults. Inotuzumab ozogamicin is recommended, within its marketing authorisation, as an option for treating relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia

Review of the evidence in relation to the treatment criteria for Ibrutinib: Letter from Professor Peter Clark – NHS England

This letter, sent to Professor Stephen Powis, provides information about the re-examination of the commissioning treatment criteria for the use of ibrutinib in previously treated patients with chronic lymphocytic leukaemia (CLL).

Arsenic trioxide for treating acute promyelocytic leukaemia: Technology appraisal guidance [TA526] – NICE

Evidence-based recommendations on arsenic trioxide (Trisenox) for treating acute promyelocytic leukaemia in adults.  

Patient access to ibrutinib for previously treated chronic lymphocytic leukaemia in England – NHS England

This clinical statement gives details about patient access to ibrutinib for chronic lymphocytic leukaemia. It states NHS is funding the cancer drug in line with NICE recommendations.